<DOC>
	<DOCNO>NCT01821235</DOCNO>
	<brief_summary>The NO SWITCH list base hypothesis pharmacokinetic difference different batch one medicine small pharmacokinetic difference two medicine ( different manufacturer , e.g . brand versus generic medicine ) . The aim study investigate hypothesis use gabapentin test product . Therefore , first objective study investigate individual bioequivalence - switchability - Gabasandoz® 800 mg relative Neurontin 800 mg® . The second objective investigate individual bioequivalence two different batch medicine , Gabasandoz® 800 mg Neurontin® 800 mg .</brief_summary>
	<brief_title>Evaluation Individual Bioequivalence Gabasandoz® Relative Neurontin® Healthy Volunteers</brief_title>
	<detailed_description>At end 2011 , Belgian Federal Agency Medicines Health Products ( FAMHP ) introduce list medicine , call 'NO SWITCH ' list1 . This list contain 42 active pharmaceutical ingredient narrow therapeutic index ( i.e . small difference effective toxic concentration ) , toxic ingredient antiepileptic . For active ingredient NO SWITCH-list , FAMHP advise , treatment start medicine particular manufacturer , continue treatment exactly medicine ( manufacturer ) . In word , switch e.g . Neurontin® 800 mg Gabasandoz® 800 mg treatment recommend . However , switch possible , do carefully supervision physician . The NO SWITCH list base hypothesis pharmacokinetic difference different batch one medicine small pharmacokinetic difference two medicine ( different manufacturer , e.g . brand versus generic medicine ) . The aim study investigate hypothesis use gabapentin test product . Therefore , first objective study investigate individual bioequivalence - switchability - Gabasandoz® 800 mg relative Neurontin 800 mg® . The second objective investigate individual bioequivalence two different batch medicine , Gabasandoz® 800 mg Neurontin® 800 mg . This two-parted study . The first part 6 way crossover pilot study 12 healthy volunteer ( men woman ) . Data pilot study use determine follow pharmacokinetic parameter : AUC0-t , AUC , Cmax T1/2 . The obtain data use develop Limited Sampling Strategy ( LSS ) , i.e . strategy determine AUC Cmax limit number plasma concentration . A simulation study perform , use data pilot study determine amount volunteer need result appropriate statistical power . This simulation study perform accord FDA Guidance Industry : Statistical Approaches Establishing Bioequivalence2 . Part two study 6 way crossover AUC Cmax determine use develop Limited Sampled Strategy .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>Healthy male female age 18 55 year screen , extremes include . A Body Mass Index 18.0 30.0 kg/m² . Good physical mental health . Subject nonsmoker least 3 month prior dose . Clinically relevant abnormal laboratory , ECG recording , vital sign physical finding screen judged investigator . History hypersensitivity idiosyncrasy gabapentin anticonvulsive agent . Positive serology hepatitis B antigen , hepatitis C antibody , HIV 1 HIV 2 antibody . History alcohol drug abuse within last 2 year . Blood donation within 1 month screening . Female subject pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>